Alpha-5 Integrin
About Alpha-5 Integrin
Monoclonal antibodies are developed by Alpha-5 Integrin for addressing neurological and psychiatric conditions. Proprietary formulations are targeted at diseases such as Amyotrophic Lateral Sclerosis and related disorders. Operations are conducted within the biotechnology sector, emphasizing therapeutic advancements in neurology. Focus is placed on innovative antibody-based solutions to support clinical treatments for brain health issues.
-
Sectors
Healthcare
-
Phone
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Alpha-5 Integrin
Detailed funding history for Alpha-5 Integrin
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Alpha-5 Integrin
Alpha-5 Integrin has secured backing from 1 investor. Prominent investors backing the company include Pasithea.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pasithea is focused on developing treatments for neurological disorders.
|
Locked | Locked | Locked |
Investor details for Alpha-5 Integrin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alpha-5 Integrin
Investment portfolio details for Alpha-5 Integrin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alpha-5 Integrin
Detailed financials for Alpha-5 Integrin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alpha-5 Integrin Comparisons
Peer comparison for Alpha-5 Integrin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alpha-5 Integrin
Detailed competitors of Alpha-5 Integrin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alpha-5 Integrin
Complete news archive for Alpha-5 Integrin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alpha-5 Integrin
Monoclonal antibodies are developed by Alpha-5 Integrin for addressing neurological and psychiatric conditions. Proprietary formulations are targeted at diseases such as Amyotrophic Lateral Sclerosis and related disorders. Operations are conducted within the biotechnology sector, emphasizing therapeutic advancements in neurology. Focus is placed on innovative antibody-based solutions to support clinical treatments for brain health issues.
Alpha-5 Integrin has 1 investor. Key investors include Pasithea.